MedTrace Logo

UCMSCs Combined With Standard Therapy for the Treatment of Newly Diagnosed Type 1 Diabetes

NCT06407297 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2024-12-27

No results posted yet for this study

Summary

The aim is to investigate the safety and tolerability of intravenous infusion of allogeneic umbilical cord mesenchymal stem cells in pediatric patients diagnosed with newly onset type 1 diabetes

Conditions

  • Newly Diagnosed Type 1 Diabetes Mellitus

Interventions

DRUG

UCMSCs

Peripheral intravenous infusion of umbilical cord mesenchymal stem cells

DRUG

Placebo

Peripheral intravenous infusion of Placebo

Sponsors & Collaborators

  • Shanghai Changzheng Hospital

    lead OTHER

Principal Investigators

  • Hao Yin · Shanghai Changzheng Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
8 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-05-23
Primary Completion
2025-09-30
Completion
2026-05-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06407297 on ClinicalTrials.gov